Page 20 - 2022-23-中国全科医学

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2833·

2006，1（5）：940-951. DOI：10.2215/CJN.00240106. spironolactone or eplerenone in combination with ACEI/ARBs in
［68］SAKLAYEN M G，GYEBI L K，TASOSA J，et al. Effects of patients with diabetic kidney disease［J］. Pharmacotherapy，
additive therapy with spironolactone on proteinuria in diabetic 2021，41（12）：998-1008. DOI：10.1002/phar.2633.
patients already on ACE inhibitor or ARB therapy：results of ［80］Kidney Disease：Improving Global Outcomes （KDIGO） Diabetes
a randomized，placebo-controlled，double-blind，crossover Work Group. KDIGO 2020 clinical practice guideline for diabetes
trial［J］. J Investig Med，2008，56（4）：714-719. DOI： management in chronic kidney disease［J］. Kidney Int，2020，98
10.2310/JIM.0b013e31816d78e9. （4S）：S1-115. DOI：10.1016/j.kint.2020.06.019.
［69］BAKRIS G L，AGARWAL R，ANKER S D，et al. Effect ［81］GARLA V，KANDURI S，YANES-CARDOZO L，et al.
of finerenone on chronic kidney disease outcomes in type 2 Management of diabetes mellitus in chronic kidney disease［J］.
diabetes［J］. N Engl J Med，2020，383（23）：2219-2229. Minerva Endocrinol，2019，44（3）：273-287. DOI：10.23736/
DOI：10.1056/NEJMoa2025845. S0391-1977.19.03015-3.
［70］LABONTé E，GROSS C，WEIR M，et al. Insulin therapy for ［82］CHEN T K，KNICELY D H，GRAMS M E. Chronic kidney disease
diabetes does not modify the effect of patiromer on serum potassium diagnosis and management：a review［J］. JAMA，2019，322（13）：
in hyperkalemic patients with type 2 diabetes on raas inhibitors［J］. 1294-1304. DOI：10.1001/jama.2019.14745.
Endocrine Practice，2017，23（1）：41A. ［83］DOSHI S M，FRIEDMAN A N. Diagnosis and management of type
［71］BAKRIS G L，PITT B，WEIR M R，et al. Effect of patiromer 2 diabetic kidney disease［J］. Clin J Am Soc Nephrol，2017，
on serum potassium level in patients with hyperkalemia and 12（8）：1366-1373. DOI：10.2215/CJN.11111016.
diabetic kidney disease：the AMETHYST-DN randomized ［84］WU B C，BELL K，STANFORD A，et al. Understanding CKD
clinical trial［J］. JAMA，2015，314（2）：151-161. DOI： among patients with T2DM：prevalence，temporal trends，
10.1001/jama.2015.7446. and treatment patterns-NHANES 2007-2012［J］. BMJ
［72］NASIR K，AHMAD A. Treatment of hyperkalemia in patients Open Diabetes Res Care，2016，4（1）：e000154. DOI：
with chronic kidney disease：a comparison of calcium polystyrene 10.1136/bmjdrc-2015-000154.
sulphonate and sodium polystyrene sulphonate［J］. J Ayub Med ［85］ANDERS H J，HUBER T B，ISERMANN B，et al. CKD in
Coll Abbottabad，2014，26（4）：455-458. diabetes：diabetic kidney disease versus nondiabetic kidney
［73］PITT B，BAKRIS G L，WEIR M R，et al. Long-term effects disease［J］. Nat Rev Nephrol，2018，14（6）：361-377.
of patiromer for hyperkalaemia treatment in patients with mild DOI：10.1038/s41581-018-0001-y.
heart failure and diabetic nephropathy on angiotensin-converting ［86］KOYE D N，MAGLIANO D J，REID C M，et al. Risk of
enzymes/angiotensin receptor blockers：results from AMETHYST- progression of nonalbuminuric CKD to end-stage kidney disease
DN［J］. ESC Heart Fail，2018，5（4）：592-602. DOI： in people with diabetes：the CRIC （chronic renal insufficiency
10.1002/ehf2.12292. cohort） study［J］. Am J Kidney Dis，2018，72（5）：653-
［74］BEST P J，STEINHUBL S R，BERGER P B，et al. The efficacy 661. DOI：10.1053/j.ajkd.2018.02.364.
and safety of short- and long-term dual antiplatelet therapy in ［87］KDIGO 2012 clinical practice guideline for the evaluation and
patients with mild or moderate chronic kidney disease：results from management of chronic kidney disease ［J］. Kidney Int Suppl，
the Clopidogrel for the Reduction of Events During Observation 2013，3（1）：1-150.
（CREDO） trial［J］. Am Heart J，2008，155（4）：687-693. ［88］HAHR A J，MOLITCH M E. Management of diabetes mellitus in
DOI：10.1016/j.ahj.2007.10.046. patients with CKD：core curriculum 2022［J］. Am J Kidney Dis，
［75］KITAMURA K，HAYASHI K，ITO S，et al. Effects of SGLT2 2022，79（5）：728-736. DOI：10.1053/j.ajkd.2021.05.023.
inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic ［89］中国医师协会内分泌代谢科医师分会 . 2 型糖尿病合并慢性肾
and antihypertensive medications［J］. Hypertens Res，2021， 脏病口服降糖药用药原则中国专家共识（2019 年更新版） ［J］.
44（5）：508-517. DOI：10.1038/s41440-020-00590-1. 中华内分泌代谢杂志，2019，35（6）：447-454.
［76］SHAO S C，CHANG K C，LIN S J，et al. Favorable pleiotropic ［90］Kidney Disease：Improving Global Outcomes（KDIGO）Blood
effects of sodium glucose cotransporter 2 inhibitors：head-to-head Pressure Work Group. KDIGO 2021 clinical practice guideline for
comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes the management of blood pressure in chronic kidney disease［J］.
patients［J］. Cardiovasc Diabetol，2020，19（1）：17. DOI： Kidney Int，2021，99（3S）：S1-87. DOI：10.1016/j.
10.1186/s12933-020-0990-2. kint.2020.11.003.
［77］YANG H，CHOI E，PARK E，et al. Risk of genital and urinary ［91］PUGH D，GALLACHER P J，DHAUN N. Management of
tract infections associated with SGLT-2 inhibitors as an add-on hypertension in chronic kidney disease［J］. Drugs，2019，79（4）：
therapy to metformin in patients with type 2 diabetes mellitus：a 365-379. DOI：10.1007/s40265-019-1064-1.
retrospective cohort study in Korea［J］. Pharmacol Res Perspect， ［92］STEPHENS J W，BROWN K E，MIN T. Chronic kidney disease
2022，10（1）：e00910. DOI：10.1002/prp2.910. in type 2 diabetes：implications for managing glycaemic control，
［78］DENNIS J M，HENLEY W E，WEEDON M N，et al. Sex and BMI cardiovascular and renal risk［J］. Diabetes Obes Metab，2020，
alter the benefits and risks of sulfonylureas and thiazolidinediones 22（Suppl 1）：32-45. DOI：10.1111/dom.13942.
in type 2 diabetes：a framework for evaluating stratification using ［93］HAGER M R，NARLA A D，TANNOCK L R. Dyslipidemia in
routine clinical and individual trial data［J］. Diabetes Care， patients with chronic kidney disease［J］. Rev Endocr Metab
2018，41（9）：1844-1853. DOI：10.2337/dc18-0344. Disord，2017，18（1）：29-40. DOI：10.1007/s11154-016-
［79］AN J，NIU F，SIM J J. Cardiovascular and kidney outcomes of 9402-z.